"The double-edged sword of inflated help": Unravelling the motivation crowding in community question-answering platforms.

The growth of digital platforms has led to the proliferation of Online Communities, providing individuals with opportunities to seek help and share knowledge. A key challenge of help-related platforms that address technical questions (i.e.

Openness as Organizing Principle: Introduction to the Special Issue.

'Openness' has become an organizational leitmotif of our time, spreading across a growing set of organizational domains. However, discussions within these specialized domains (e.g.

Expertise Diversity, Informal Leadership Hierarchy, and Team Knowledge Creation: A study of pharmaceutical research collaborations.

Knowledge creation increasingly requires experts from diverse domains to collaborate in teams, yet the effect of expertise diversity on team knowledge creation is inconclusive. We focus on task uncertainty and informal leadership hierarchies - the disparity in team members' engagement in leadership activities (task- and relationship-oriented) - to answer the questions when and why expertise diversity may hinder team knowledge creation. We develop a model in which informal leadership hierarchy mediates the conditional indirect effect of the team's expertise diversity on its knowledge creation under different levels of task uncertainty.

How do healthcare providers construe patient complexity? A qualitative study of multimorbidity in HIV outpatient clinical practice.

Introduction: Patient complexity is an increasingly used concept in clinical practice, policy debates and medical research. Yet the literature lacks a clear definition of its meaning and drivers from the health provider's perspective. This shortcoming is problematic for clinical practice and medical education in the light of a rising number of multimorbid patients and the need for future healthcare providers that are adequately trained in treating complex patients.

Rethinking leadership in drug discovery projects.

Great efforts have been dedicated to rebuilding the engine of pharmaceutical R&D. However, one potential area of improvement has received limited attention in the literature and in practice: namely, leadership. In this article, we enrich the traditional views of leadership, which consider leadership a responsibility of a few centrally placed authorities, with the concept of distributed leadership.

Clusters in the biopharmaceutical industry: toward a new method of analysis.

Clusters are groups of co-located and interconnected firms and institutions linked by commonalities in their strategies and complementarities in their activities and resources. There are several reasons for the geographical clustering of firms in the biopharmaceutical industry. This review unpacks some advantages and disadvantages of cluster participation, and proposes a new method to enable managers and researchers to identify clusters in the biopharmaceutical industry.

Strategic groups in the biopharmaceutical industry: implications for performance.

The biopharmaceutical industry is characterized by intense competition, high uncertainty, and strong dependence on scientific knowledge. We show that in order to succeed in this industry, firms need to be positioned along three strategic dimensions: the level of inter-firm R&D partnering, the level of diversification, and the size of the firm. Prior research has revealed that a firm's membership in so-called 'strategic groups' impacts strongly on its performance.